Clinical Trial Update: Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes [Phase 1, Phase 2]

View source ↗

Summary

Adaptive study evaluating how different IL-2 dose frequencies affect regulatory T cells in individuals with Type 1 Diabetes; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Interleukin-2 (IL-2) (interleukin-2)

Snippet

Sponsor: Cambridge University Hospitals NHS Foundation Trust | Conditions: Type 1 Diabetes | Phase 1, Phase 2 | Status: COMPLETED